Bristol Breyanzi OKd as New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

 In the MCL cohort of TRANSCEND NHL 001, Breyanzi delivered responses in 85.3% of patients with a one-time infusion while demonstrating a consistent safety profile across clinical trials

Breyanzi is the only CAR T cell therapy approved by the FDA for four distinct subtypes of non-Hodgkin lymphoma, bringing this personalized therapy to the broadest array of patients with B-cell malignancies

https://www.businesswire.com/news/home/20240523741069/en/Product